AACR: Three Promising Anticancers From Loxo Oncology, Ignyta And BeiGene

Investigational anticancer drugs aimed at new potential targets, particularly those involving genetic abnormalities that can be identified for diagnostic purposes, were the focus of presentations on their safety and efficacy in Phase I studies at this year's American Association for Cancer Research (AACR) meeting, being held in New Orleans on Apr. 16-20.